CLPT · ClearPoint Neuro, Inc.
$15.19
-0.77 (-4.82%)
At close · Aug 20
Market Cap
$484.71M
Shares
30.50M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.19
Open$15.77
Day$15.18–16.08
52W close$8.66–29.60
Avg vol 30d584K
Short int3.9M · 12.8% float · 7.5d
Short vol58%
Last earningsAug 3, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
−3%
below
RSI (14)
51
neutral
MACD trend
Positive
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+21%
trailing
YTD return
+11%
this year
Relative strength
+10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +21 funds added
Insider flow
Distributing
Net -$65.9K over 90 days · 100% sells
Short interest
Rising
12.77% of float · ▲ +5.4% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
129 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
+18%
Y/Y
Gross margin
61%
expanding
EPS growth
−29%
Y/Y
Free cash flow
$-24.4M
Balance sheet
$3.2M
net debt
Quant / Vol
risk profile
Volatility
106%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
Revenue
· 2026
$48M – $52M
prior FY $36.97M
midpoint +35.2% Y/Y
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Revenue
· full year 2025
$36M – $38M
Guided vs delivered
· last 3 settled
Revenue
full year 2025
guided $36M – $38M
$36.97M
In line
Revenue
2024
guided $28M – $32M
$31.39M
In line
Revenue
2023
guided $23M – $25M
$23.96M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +21 funds added
Insider flow
Distributing
Net -$65.9K over 90 days · 100% sells
Short interest
Rising
12.77% of float · ▲ +5.4% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
129 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $15 · 31%
Range high $30
vs 200-day avg +13%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| activated installed base across all ClearPoint technology including IRRAflow systems | 175 | Q1 2026 | — |
| active biopharma partners | 60 | Q1 2026 | — |
| gross margin | 64% | Q1 2026 | — |
|
|
|||
| installed base of global centers | 150 | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLPT
this stock
ClearPoint Neuro, Inc.
|
$484.71M | +11.0% | +17.8% | — | 12.8% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLPT | -1.5% | +4.8% | +20.8% | +1.7% | +11.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.5% | +1.5% | +9.7% | -0.4% | -0.8% |
Key facts
CIK
1285550
CUSIP
18507C103
13F (30d)
122 filings
120 filers
Visit website
Investor relations